ArticleResearch square2026
Genome-scale molecular profiling from routine histopathology with a multimodal pathology foundation model.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Pathology foundation models trained from whole-slide images alone treat tissue morphology as an autonomous visual phenotype, leaving learned representations only weakly anchored to the molecular processes that generate tissue architecture. Here we present Fuji, a multimodal pathology foundation model that grounds morphology in transcriptomic and mutational supervision through a two-stage pretraining strategy: multi-teacher contrastive distillation that harmonizes formalin-fixed paraffin-embedded and fresh-frozen specimens, followed by multimodal multi-task learning that jointly optimizes masked image reconstruction, transcriptomic embedding reconstruction, and attention-aligned mutational signature inference. Trained on 60,546 whole-slide images paired with 45,675 bulk RNA-seq profiles and 22,683 whole-genome sequencing samples drawn from TCGA, GTEx, and CPTAC, Fuji yields a protocol-invariant, genome-informed embedding that we treat as a quantitative coordinate system for probing how genomic states project into tissue architecture. Genome-scale instability phenotypes, microsatellite instability, chromosomal instability, homologous recombination deficiency, and whole-genome duplication, are recoverable from histology with AUCs up to 0.98, consistently exceeding existing pathology foundation models. Extrachromosomal DNA amplification leaves a distinct morphological footprint that stratifies survival independently of tissue lineage. Etiologic mutational processes such as tobacco exposure and mismatch repair deficiency localize to discrete architectural neighborhoods, validated in two independent population-based cohorts, whereas clock-like signatures remain diffuse, delineating the scope and limits of genomic visibility from routine histology. Fuji further enables direct inference of tumor mutational burden, neoantigen load, immunotherapy response, and FDA-actionable driver mutations from hematoxylin and eosin slides. By coupling pretraining to molecular and mutational supervision, Fuji establishes an engineering basis for genome-informed inference from the most widely performed assay in oncology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.